IDP Pharma has closed a 1,5M€ seed investment round. The private funding adds to the 1,2M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ) in collaboration with Leitat, University of Salamanca (FICUS) and BCN Peptides. The company will allocate the capital to advance the preclinical development of its first product for cancer treatment and to continue developing its technology: IDP-Platform.

IDP Pharma will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an expansive exhibition floor, and exclusive networking events where you will access over 2,500 CEO’s from leading biotech companies.